Multiple Sclerosis

Excellence Forums

Leaders in the field sharing authoritative insights and institutional best practices.
In this podcast, Dr Coyle discusses the "final word" on strategies to promote remyelination in multiple sclerosis from the ECTRIMS/ACTRIMS MSVirtual2020 meeting.
In this video, Amit Bar-Or, MD, FRCPC, gives an overview of encouraging findings regarding the long-term safety of ozanimod for relapsing forms of multiple sclerosis.
Mahsa Dadar, PhD, answers our questions about her new study that suggested diffusely abnormal white matter regions in the brain evolve into focal white matter lesions over time in secondary progressive multiple sclerosis, which in turn may be associated with clinical disease progression.
In this podcast, Dr Coyle discusses the "final word" on myelin oligodendrocyte glycoprotein-mediated disease in multiple sclerosis from the ECTRIMS/ACTRIMS MSVirtual2020 meeting.
Shiv Saidha, MBBCh, answered our questions about his study, which suggests that elevated body mass index may be associated with accelerated ganglion cell + inner plexiform layer atrophy in the absence of overt metabolic comorbidities among patients with multiple sclerosis.
In this video, Amit Bar-Or, MD, FRCPC, discusses new long-term data that show a favorable safety profile over time with the use of ozanimod among patients with relapsing forms of multiple sclerosis.
In this podcast, Dr Coyle discusses the "final word" on neuromyelitis optica spectrum disorder in multiple sclerosis from the ECTRIMS/ACTRIMS MSVirtual2020 meeting.
In a recent nested case-control study, researchers investigated the effects of tumor necrosis factor inhibitor exposure on the risk of inflammatory demyelinating and nondemyelinating central nervous system events. Study author Amy Kunchok, MBBS, MMed, from the Mayo Clinic, answered our questions about this research.
At the ANA’s 145th Annual Meeting, Caterina Mainero, MD, PhD, discussed gray matter pathology in multiple sclerosis. After Dr Mainero’s presentation, Neurology Learning Network caught up with her about important research advances in this area.
Prodromes are well documented for neurodegenerative disorders such as Parkinson disease and Alzheimer disease, and there are increasing data for a multiple sclerosis (MS) prodrome, writes Patricia K. Coyle, MD, from Stony Brook University. In this commentary, Dr Coyle reviews evidence of prodromal MS.
In a recent study, researchers investigated whether autofluorescence may serve as a marker of prior and ongoing white matter injury in chronic neurological diseases such as multiple sclerosis. Neurology Learning Network discussed the findings and their implications further with study author Andrew Caprariello, PhD.